NRX Pharmaceuticals, Inc. (NRXP) Form 10-Q — May 15, 2026
NRX Pharmaceuticals reported a net loss of $1.4 million for the quarter ended March 31, 2026, driven by operating expenses of $5.8 million that outpaced $1.1 million in new patient service revenue from its HOPE Therapeutics subsidiary. The company disclosed substantial doubt about its ability to continue as a going concern, citing a working capital deficit of $17.8 million and a stockholders' deficit of $13.8 million, with only $6.7 million in cash on hand. Management stated it has secured capital sufficient to fund drug development through Q3 2026 but may need to pursue additional equity or debt financing, which could result in further dilution to existing shareholders.
Key figures
- Revenue
- 1068000
- Total Debt
- 25719000
- Total Assets
- 11903000
- Cash Position
- 6713000
- Shares Outstanding
- 36228992
- Atm Proceeds Q1
- 3424000
- Warrant Liabilities
- 8766000
- Refund Liability Alvogen
- 5638000
Price after filing
Close on the filing date to close N calendar days later (from $3.21). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.